The American Cancer Society estimates that in 2017 alone, there will be more than 1.6 million new cases of cancer and 600,000 cancer deaths in the United States. With estimates like these, the need for new cancer treatments is more important than ever, and America’s biopharmaceutical companies are boldly leading the way in discovering new breakthroughs.
PhRMA, in partnership with the American Cancer Society Cancer Action Network (ACS CAN), announced today in a new report that there are more than 240 immuno-oncology medicines and vaccines in development to treat cancer. These immuno-oncology medicines, otherwise known as immunotherapies, are novel in the way they use the body’s own immune system to fight cancer, similar to how the immune system would attack a virus or bacteria.
There are multiple classes of innovative immunotherapies, and the report includes treatments in development in the most recognized classes, including adoptive cell therapies (including CAR-T therapy), bi-specific antibodies, cytokines, immune checkpoint modulators, oncolytic virus therapies and vaccines. It also details how researchers are working to understand the full potential of each individual medicine, seeking approval for new indications for existing immunotherapies and new uses in combination with other cancer medicines.
The report was released as part of PhRMA’s GOBOLDY campaign, which showcases the bold advancements the industry is making in tackling our most complex and devastating health conditions through innovative research. While the biopharmaceutical industry is a leader in the development of innovative treatments, it also plays a critical role along with others in the health care ecosystem to help bring new medicines to patients.
To learn more about the “Medicines in Development for Immuno-Oncology” report click here.
Andrew Powaleny
Andrew Powaleny is the Deputy Vice President of Public Affairs at PhRMA, where he leads communications on scientific, regulatory and intellectual property issues, highlighting the biopharmaceutical industry’s efforts in developing innovative medicines and vaccines while promoting an environment that encourages necessary risk-taking. For five years starting in 2019, he launched and led PhRMA’s grassroots initiative, Voters for Cures, bringing patients and caregivers together to advocate for access to medicine and biopharmaceutical innovation. He also co-founded and co-chaired PRIDE Umbrella, a resource group for LGBTQ+ individuals. Prior to joining PhRMA in 2015, Andrew worked as a communications consultant in Washington, D.C., and as Deputy Press Secretary for the U.S. House Committee on Energy and Commerce under Chairman Fred Upton. He holds a degree in public policy and government from Eastern Connecticut State University, with a minor in music. Outside of work, Andrew enjoys exercise, musical theater and mentoring college students through The Fund for American Studies alumni association.
Andrew Powaleny
New study: HPV vaccination helps prevent cervical cancer deaths
America's cancer research progress is real and worth protecting
Ahead of ASCO: Cancer innovation is promising, but policy choices matter
Advancing patient care: A look at new medicines approved in 2025
CAREs 2025: Supporting community-based solutions that improve access to medicines
New analysis finds 340B hospitals push patients toward costly care to boost profits
Price setting policies put cancer gains in jeopardy
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
Guest Perspective: Prioritize Innovative Care
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.
The Patient Perspective: Vaccines
The importance of partnership: A conversation with Takeda
New Report: Tackling chronic conditions with preventive treatment
New Report: Vaccines continue to drive improved health outcomes
The future of oncology R&D lies in policymakers’ hands
Showcasing the promise of biopharma at ASCO 2024
Mental Health Awareness Month: Supporting loved ones and improving mental health in America
Championing cancer equity: Our drive for healthier AANHPI communities
The impact of innovative medicines: A caregiver's perspective
PhRMA awards $250,000 to community-based projects to improve equitable cancer outcomes
Three things to know about antibody drug conjugates
The IRA’s pill penalty threatens the future of oncology R&D
New Report: 1,600 cancer treatments and vaccines in clinical development
R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot
Watch: New video series spotlights advances in biopharmaceutical science
Between hope and despair: Improving cancer outcomes
New report shows high-impact R&D happens after cancer medicines are first approved
New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines
ASCO 2023: Protecting our progress in the fight against cancer
Highlights from ASCO 2023
Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation
Support for continued progress is critical for pediatric drug development
New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans
IRA Impacts: Cancer treatment research and development
State policymakers can protect American innovation and help Americans live longer, healthier lives
Recognizing National Glaucoma Awareness Month
New Report More than 160 medicines in development for mental illness
ICYMI: Cancer death rate continues to decline due to treatment advances
Novel medicines approved in 2022 offer increased treatment options for patients
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
ICYMI: PhRMA COO Lori Reilly Esq. speaks with Jacob Van Naarden about the future of cancer research
Protecting treatment advances for breast cancer
New Report: Nearly 800 medicines in development to treat chronic conditions
Recognizing National Sickle Cell Awareness Month
Key takeaways from ASCO's annual meeting
Potential gene therapies bring hope to patients with sickle cell disease
ICYMI: First pediatric patient to receive CAR-T cell therapy celebrates 10 years of being cancer-free
Gene therapies can reduce treatment burden and costs for patients with blood disorders
Report: More than 500 medicines in development to treat disorders of the blood
Report: More than 600 medicines in development for diseases affecting women
4 things to know about biopharmaceutical efforts to fight cancer
New data show continued decline in death rates for cancer patients related to treatment advances
New Report: Nearly 800 new medicines in development to treat rare diseases
Guest post: Continued research and development is critical for ALS patients and families
New report shows more than 260 medicines in development to fight neurodegenerative diseases
Recognizing National Immunization Awareness Month
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections
Action needed to preserve the six protected classes
ICYMI: Cancer death rate continues decline due to advances in treatment
Report: More than 1,300 medicines and vaccines in development to help fight cancer
Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015
New report explores setbacks that bring future cancer success stories
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
New report shows nearly 260 vaccines in development, including dozens for COVID-19
Nearly 400 cell and gene therapies in development to target a broad range of diseases
Cancer medicines cost twice as much at hospitals, study finds
Nearly 140 medicines in development to treat mental illness
New report shows more than 160 medicines in development for diabetes and related conditions
New report shows nearly 20 innovative medicines in development for sickle cell disease
130 medicines in development for asthma, allergies and other respiratory diseases
130 medicines in development for asthma, allergies and other respiratory diseases
New report shows nearly 300 cell and gene therapies in development
World AIDS Day 2018: Hope for the future
New report shows more than 300 skin disease medicines in development
Saving kids and dogs from shared cancers
New report details the setbacks and challenges to Alzheimer’s research
New analysis shows that more medicines worldwide are available to U.S. patients
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
A new era in Alzheimer’s innovation
Spending on medicines grew less than one percent in 2017
New report shows over 500 medicines in development for neurological disorders
Patients pay the price when hospitals mark up cancer medicines
Guest post: Advancing healthy hearts for patients
Rare Disease Day: Unmet need inspires innovation
New report shows 200 medicines in development for heart disease and stroke
Record number of personalized medicines approved in 2017
World AIDS Day 2017: Scientific breakthroughs paving the way for an AIDS-free generation
A new era in cancer
PhRMA, member companies and NIH create public-private partnership for immuno-oncology
2017 Research & Hope Awards honor innovators in mental health
What they are saying: Study on cancer R&D costs is not an accurate representation of marketplace
Protect your health: Important disaster preparedness tips for Harvey and Irma
Medicare Monday: Strengthening access to vaccines for seniors
Finding cures for incurable diseases
New report portrays flourishing pipeline
More than 50 medicines and vaccines in development for HIV infection, treatment and prevention
Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines
Medicines have significantly increased chances of cancer survival around the globe
ICYMI: The New Era of Medicine initiative spotlights genomics in NYC
ICYMI: Report highlights overall decrease in cancer death rates
This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system
The 20-year journey yielding a new weapon against cancer
Significant progress fighting cancer: Death rate has dropped 25 percent
3 things to know about 2016 drug approvals
More than 240 immuno-oncology treatments in development to fight cancer
Cancer
Medicines in Development
Personalized Medicine
More than 240 immuno-oncology treatments in development to fight cancer
More than 240 immuno-oncology treatments in development to fight cancer